Can You Go Into V Tach With a Pacemaker?

Ventricular tachycardia in someone with a pacemaker or implantable cardioverter-defibrillator is a two-sided problem: the device can sometimes provoke it, and in other configurations it can stop it. Whether a pacemaker is part of the cause or part of the cure depends on the type of device, where its leads sit, how much it paces, and the underlying condition of the heart muscle. Understanding how these factors interact matters because the clinical decisions around pacing in VT-prone patients are genuinely consequential, and some of them are counterintuitive.

How Pacing Itself Can Trigger Ventricular Tachycardia

It sounds paradoxical that a device meant to stabilize heart rhythm could make dangerous rhythms more likely, but this is well-documented. The most straightforward mechanism involves right ventricular pacing. When a pacemaker fires from the right ventricle, it forces the heart to contract in an abnormal sequence, starting from the pacing lead rather than propagating through the normal conduction system. Over time, this unnatural activation pattern causes structural changes: the heart muscle thickens unevenly, the arrangement of muscle fibers becomes disorganized, and the local chemistry of the heart shifts in ways that make arrhythmias easier to start.

In patients who already have weakened hearts, these changes carry real consequences. A study from the MADIT-II trial found that patients who were frequently paced in the right ventricle had roughly 50% higher odds of needing ICD therapy for VT or ventricular fibrillation compared to those who were paced infrequently, along with nearly double the risk of new or worsening heart failure.¹ A separate analysis confirmed the threshold: patients paced more than half the time had a significantly higher risk of appropriate shocks for VT or VF, even after adjusting for other factors like ejection fraction and atrial fibrillation history.²

The biological explanation ties these observations together: right ventricular pacing causes mechanical dyssynchrony that degrades heart function, alters sympathetic nerve activity, and changes the behavior of ion channels in heart cells. In animal models, it produces asymmetric thickening and increased catecholamine concentrations in the heart muscle, both of which create conditions ripe for re-entrant circuits to form.³ This is one reason modern programming strategies try to minimize unnecessary right ventricular pacing whenever possible.

When the Lead Sits on Scar

The location of the pacing lead matters as much as how often it fires. In patients receiving cardiac resynchronization therapy, a left ventricular lead is placed on the outer surface of the heart, usually through a vein in the coronary sinus. If that lead happens to land on or near an area of scar tissue, it can create exactly the kind of slow-conduction zone that sustains re-entrant VT circuits. Research has shown that patients who develop VT storms shortly after CRT implantation are significantly more likely to have their left ventricular lead positioned within epicardial scar.⁴ Pacing from that spot essentially feeds energy into the scar border zone in a way that facilitates the circular electrical pathway VT requires.

This proarrhythmic risk also shows up in other clinical settings. After left ventricular assist device implantation, patients who had biventricular pacing with a left ventricular lead were found to have a higher rate of monomorphic VT in the early recovery period, reinforcing the idea that epicardial pacing can be proarrhythmic under the right (or wrong) conditions.⁵ The practical takeaway is that lead placement decisions for CRT devices now factor in scar imaging, and when new VT occurs after a CRT implant, lead position is one of the first things the team evaluates.

Anti-Tachycardia Pacing as a Painless First Response

While pacing can provoke VT, it can also terminate it, and this is one of the most important capabilities of modern ICDs. Anti-tachycardia pacing, or ATP, works by delivering a rapid burst of pacing pulses that are slightly faster than the tachycardia itself. The goal is to get ahead of the re-entrant circuit, depolarize the tissue it depends on, and break the cycle. When it works, the arrhythmia stops without the patient feeling anything beyond perhaps a brief flutter. Compare that to a defibrillator shock, which is painful and psychologically distressing.

The programming of ATP has grown more refined over time. Research into different pacing strategies has found that a less aggressive initial burst followed by more aggressive subsequent attempts can improve the success rate of ATP without increasing the chance that it accelerates the VT into something worse.⁶ Newer automated ATP algorithms built into CRT-defibrillator devices have shown the ability to terminate sustained monomorphic VT that conventional burst pacing from a catheter could not stop, and in electrophysiology studies the termination was reproducible.⁷

ATP is most effective for monomorphic VT at moderate rates. Faster VTs, polymorphic VT, and ventricular fibrillation usually require a shock. Most ICDs are programmed to attempt one or more rounds of ATP before escalating to shock delivery, which means many VT episodes are terminated silently. A patient may have dozens of VT events successfully treated by ATP without ever knowing unless they review their device records.

Reverse Remodeling and Why CRT Can Cut VT Risk

The same CRT that can occasionally provoke VT through scar-based lead placement can, when it works well, substantially reduce VT risk over time. The mechanism is reverse remodeling: when CRT successfully resynchronizes a failing heart, the left ventricle shrinks, the ejection fraction improves, and the substrate that supports VT circuits becomes less favorable.

Data from the MADIT-CRT trial showed a clear dose-response relationship. Patients who responded strongly to CRT (measured by reduction in left ventricular end-systolic volume) had a 55% lower risk of ventricular tachyarrhythmias compared to patients receiving an ICD alone, while patients who responded poorly had no significant reduction at all.⁸ For every 10% reduction in end-systolic volume, the risk of VT dropped in a corresponding, incremental way. A separate study found that anatomical responders to CRT had almost half the rate of PVC runs and fewer treated VT/VF episodes than non-responders.⁹

This creates a nuanced picture: CRT is both a potential short-term proarrhythmic threat (especially with poor lead positioning) and a powerful long-term anti-arrhythmic tool (when reverse remodeling occurs). How much a patient benefits depends on whether their heart responds to resynchronization, and about a third of CRT recipients do not respond meaningfully. Perfusion imaging after CRT implantation has been explored as a way to predict which patients will see reverse remodeling and a corresponding drop in VT risk.¹⁰

Electrical Storm in Device Patients

Electrical storm, defined as three or more episodes of sustained VT or VF within 24 hours, is one of the most frightening emergencies in cardiology. For patients with ICDs, it means repeated shocks in quick succession, each one painful, each one amplifying the distress. Managing electrical storm requires a layered approach: first, find and fix reversible triggers like low potassium, active ischemia, or new medication effects. Intravenous beta-blockers (propranolol in particular) and amiodarone are the pharmacologic workhorses and resolve the arrhythmia in most patients.¹¹

When drugs fail, catheter ablation targeting the VT circuit is the next step. In drug-refractory cases, sympathetic neuromodulation or even temporary mechanical circulatory support may be needed to stabilize the patient long enough for definitive treatment.¹² Device reprogramming during a storm is also critical. The ICD’s detection zones, ATP settings, and shock thresholds may need adjustment so the device is helping rather than reflexively shocking in a way that adds to the cycle. A device that delivers repeated shocks without stopping the underlying rhythm is not therapeutic; it is traumatic and consumes battery life.

Device Malfunctions That Mimic VT

Not every high-rate event the device registers is genuine VT. A phenomenon called oversensing occurs when the device misinterprets electrical signals it should ignore (like T-waves, muscle artifact, or electromagnetic noise) as rapid ventricular beats. This can trigger inappropriate shocks for a rhythm that was never there. Lead fractures and connection problems are among the most dangerous causes of oversensing because they produce rapid, irregular signals that closely mimic VF, prompting the device to shock repeatedly.¹³ Physiologic oversensing, like T-wave oversensing, can often be resolved by reprogramming the device’s sensitivity. Lead issues typically require surgical intervention.

At the more extreme end, there is the runaway pacemaker. This rare malfunction occurs when the pulse generator loses its programmed rate control and begins firing at very high rates, effectively driving the ventricle into tachycardia. It is a hardware failure rather than a sensing problem, and it requires urgent attention, usually a magnet placed over the device to inhibit pacing while the patient is transported for generator replacement.¹⁴

Modern devices also have dual-chamber discrimination algorithms designed to differentiate VT from fast supraventricular rhythms like atrial fibrillation or atrial flutter conducted to the ventricles. These algorithms compare atrial and ventricular rates, look at the onset pattern, and evaluate the regularity of the rhythm before deciding whether to deliver therapy. They have become sophisticated enough to prevent most inappropriate shocks, though no algorithm is perfect.¹⁵

Pacemaker-Mediated Tachycardia

There is another kind of device-related tachycardia that is not VT at all but can look alarming. In dual-chamber pacemakers that both sense and pace in the atrium and ventricle, a ventricular beat that happens to conduct backward to the atrium can fool the device into thinking there is an atrial event. The pacemaker then triggers a ventricular pace, which again conducts retrogradely to the atrium, and an “endless loop” tachycardia develops. The heart rate during these episodes is usually whatever the device’s upper tracking rate is set to, which can easily reach 120 to 150 beats per minute.¹⁶ This is not ventricular tachycardia in the electrophysiologic sense, but it is a device-driven rapid rhythm that can cause symptoms like palpitations, lightheadedness, and shortness of breath. Modern devices have algorithms to detect and interrupt these loops automatically, but older or improperly programmed devices may sustain them.

How Drugs Interact with Device Thresholds

Antiarrhythmic drugs are commonly used alongside pacemakers and ICDs, especially in patients with recurrent VT. But these drugs interact with the device in ways that need monitoring. Amiodarone, one of the most widely prescribed antiarrhythmics, can raise the energy threshold the heart needs to capture (respond to) a pacing pulse. In one documented case, a patient on chronic amiodarone developed a severe increase in atrial pacing threshold, leading to loss of capture, meaning the pacemaker was firing but the atrium was no longer responding. The threshold returned to normal once amiodarone was stopped, and notably the ventricular threshold was unaffected.¹⁷

For ICD patients, there is also the question of whether amiodarone raises the defibrillation threshold, potentially making shocks less effective. This was a genuine concern with older monophasic devices, but with modern biphasic shock waveforms and transvenous lead systems, the difference in defibrillation threshold between patients on chronic amiodarone and those on no antiarrhythmic therapy has not been significant.¹⁸ Still, patients on amiodarone or other antiarrhythmics need regular threshold checks at their device follow-up visits, because an undetected rise in pacing threshold could leave someone without effective pacing when they need it most.

Remote Monitoring and Catching VT Early

Most modern pacemakers and ICDs transmit data wirelessly to the clinic, allowing clinicians to review arrhythmia logs, battery status, and lead measurements without an in-person visit. For VT, remote monitoring provides an early warning system. In a study of over 500 pacemaker patients followed remotely for an average of about three years, ventricular high-rate events were flagged in roughly 37% of patients, though about a quarter of those turned out to be false detections caused by noise or oversensing rather than true arrhythmias.¹⁹ The ability to catch true VT events between scheduled visits is valuable because it allows earlier medication adjustments, earlier referral for ablation, and earlier detection of lead problems that might be causing false alarms.

Why Scar Location Shapes the VT Circuit

In patients who develop VT with any type of cardiac device, the underlying heart disease determines what the VT circuit looks like and how amenable it is to treatment. Scar from a prior heart attack tends to be dense, concentrated, and located in a predictable territory that matches the blocked coronary artery. In contrast, scar from non-ischemic cardiomyopathy is often more diffuse and extends deeper into the mid-wall or onto the outer surface of the heart. This difference has direct implications for catheter ablation: in patients with ischemic disease, the critical narrow channel (isthmus) of the VT circuit can be identified from the inner surface of the heart in roughly 62% of cases, compared to only about 17% in non-ischemic patients.²⁰

High-density mapping has shown that ischemic scar produces larger zones of dense scar on the inner surface, with more complex electrical signals and wider conducting channels within the scar, which actually makes those circuits more accessible to ablation. Non-ischemic scar, by contrast, tends to show a higher ratio of deep-to-surface scar, meaning much of the arrhythmia substrate is hidden from standard catheter approaches.²¹ For a patient with a pacemaker or ICD and recurrent VT, this distinction helps the electrophysiology team set expectations about whether ablation is likely to succeed and whether an epicardial (outside the heart) approach will be needed.

The Psychological Toll of Shocks

ICD shocks are effective at stopping VT and VF, but they come at a psychological cost that clinicians have historically underappreciated. The experience is sudden, painful, and unpredictable. Patients commonly describe it as being kicked in the chest. Repeated shocks, especially during an electrical storm, can lead to anxiety disorders and symptoms resembling post-traumatic stress disorder. Early research into interventions for shock-related distress has found that structured self-monitoring programs can reduce ICD shock anxiety and PTSD symptoms after a shock event.²² This is one of the reasons that reducing unnecessary shocks through better programming, more effective ATP, and earlier ablation has become a priority in device management, not just for physical outcomes but for quality of life.

Turning Off the ICD at End of Life

When a patient with an ICD reaches the end of life from a terminal illness, the device does not know the clinical context has changed. It will continue to detect VT and VF and deliver shocks, even when the patient is actively dying and further resuscitation is neither desired nor beneficial. These shocks cause pain and distress to both the patient and the family members witnessing them. Deactivating the shock function of an ICD in a terminally ill patient is ethically appropriate and widely supported by medical guidelines, yet the conversation about deactivation happens far less often than it should. Many patients are never asked about their preferences, and many hospice and palliative care settings lack clear protocols for managing an active ICD.²³ Deactivation does not mean turning off the pacemaker function; bradycardia pacing can continue if it provides comfort. It means disabling the shock therapy so the device does not inflict pain during a process that is already irreversible. Ideally, this conversation happens well before the end-of-life phase, as part of routine advance-care planning for anyone who receives an ICD.